Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07075523 · ClinicalTrials.gov registry record
Neuroimaging and Biomarkers of Neurotoxicity After Chimeric Antigen Receptor T-Cell Therapy
A clinical trial of CAR T-Cell Therapy, sponsored by University of California, San Diego.
- Recruiting
- Registry status
- 36
- Enrollment target
- 1
- Study location
NCT07075523 is a study of CAR T-Cell Therapy that is actively recruiting participants, run by University of California, San Diego. The registered enrollment target is 36 participants, below the 162-participant average among 3 other CAR T-Cell Therapy trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07075523, a study of CAR T-Cell Therapy, is actively recruiting participants, sponsored by University of California, San Diego.
- RECRUITING
- Registry status
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to understand why some people receiving chimeric antigen receptor (CAR) T-cell therapy for cancer experience neurotoxicity. The main question it aims to answer is: Can a novel tool be developed to identify early the patients who will develop immune effector cell-associated neurotoxicity syndrome (ICANS, also called neurotoxicity) after chimeric antigen receptor (CAR) T-cell therapy? Participants already scheduled for chimeric antigen receptor (CAR) T-cell therapy as part of the medical care for their cancer will be evaluated with advanced neuroimaging techniques. In addition, neurocognitive assessments using questionnaires and measurement of biomarkers in blood (liquid biomarkers) will be performed to provide a comprehensive characterization of neurotoxicity following chimeric antigen receptor T-cell therapy. Assessments will be performed in the acute phase (2 to 14 days after chimeric antigen receptor (CAR) T-cell therapy) and after approximately 3 months.
Conditions Studied
Interventions
- OTHER Brain magnetic resonance imaging, neurocognitive assessments, quality of life questionnaire, biomarkers
Study Locations (1)
California
- University of California, San Diego - La Jolla
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2025-09-19 |
| Est. Completion | 2027-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07075523
The ClinicalTrials.gov registry entry for NCT07075523 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 162-participant average among 3 other CAR T-Cell Therapy trials with a reported enrollment target (78% lower). The listed sponsor is University of California, San Diego, which has 775 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with CAR T-Cell Therapy appearing as the primary indexed condition, and to 1 intervention - of which Brain magnetic resonance imaging, neurocognitive assessments, quality of life questionnaire, biomarkers is the first listed.
NCT07075523 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT07075523 about?
NCT07075523 is a clinical study titled "Neuroimaging and Biomarkers of Neurotoxicity After Chimeric Antigen Receptor T-Cell Therapy". The goal of this study is to understand why some people receiving chimeric antigen receptor (CAR) T-cell therapy for cancer experience neurotoxicity. The main question it aims to answer is: Can a novel tool be developed to identify early the patients who will develop immune effector cell-associated...
What is the current status of trial NCT07075523?
This trial is currently recruiting. The enrollment target is 36 participants. The study started on 2025-09-19. Estimated completion is 2027-12.
What conditions does trial NCT07075523 study?
This clinical trial studies the following conditions: CAR T-Cell Therapy.
What interventions are being tested in trial NCT07075523?
The interventions under investigation include: Brain magnetic resonance imaging, neurocognitive assessments, quality of life questionnaire, biomarkers (OTHER).
Who is sponsoring clinical trial NCT07075523?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07075523 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for CAR T-Cell Therapy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.